tbuckley/cabot-search huggingface dataset:
PWE-041 Reduced Expression of TJP-2 Is Associated with Chronic Liver Disease and Hepatic Malignancy
Authors: SK Kamarajah, DA Patten, JCR Wadkin, C Coldham, RH Bhogal, S Shetty, CJ Weston
Journal: Gut (2016)

<h3>Introduction</h3> Tight Junction Protein–2 (TJP-2) belongs to a family of proteins that are predominantly expressed at the junctions between epithelial cells. TJP-2 has been implicated in the progression of breast and pancreatic cancer through regulation of downstream signalling pathways responsible for invasion and metastasis. Recently, gene alterations in TJP-2 have been discovered in patients with progressive familial intrahepatic cholestasis leading us to hypothesise that TJP-2 might be differentially regulated in chronic liver disease and liver cancer. Our aim was to characterise the expression of TJP-2 in liver disease with a particular focus on malignancy. <h3>Methods</h3> The cellular localization and expression of TJP-2 in human liver tissue sections was studied using immunohistochemistry, multi-colour confocal immunofluorescence and immunocytochemistry. TJP-2 mRNA expression was quantified by qRT-PCR and protein expression was determined by western blotting of tissue lysates prepared from pathological control and diseased liver samples. Image J analysis was used to quantify expression of TJP-2 in chronic liver disease and liver cancers. <h3>Results</h3> TJP-2 expression in human tissue sections was significantly downregulated in chronic liver disease and liver cancer, specifically hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), when compared to pathological control tissue. The majority of TJP-2 protein was restricted to cellular junctions of biliary epithelial cells and hepatocytes in both pathological control and chronically diseased livers. In HCC and CCA tissue sections the protein was also found to adopt a characteristic perinuclear distribution, consistent with previous studies on pancreatic cancer cell lines. Western blotting and qRT-PCR studies revealed a significant decrease in TJP-2 expression in both chronic liver disease and primary liver cancer when compared to pathological control livers. Preliminary analysis of tissue samples taken from patients who had undergone hemihepatectomy for intrahepatic cholangiocarcinoma, and who were matched for anatomical location and tumour histology, suggested a correlation between TJP-2 expression and overall survival. <h3>Conclusion</h3> This is the first report on TJP-2 expression in liver disease. TJP-2 was expressed on epithelial cells, with reduced mRNA and protein levels detected in chronic liver disease and liver cancer, suggesting that progressive loss of this molecule may contribute to altered epithelial function in hepatic injury and malignancy. Our data suggest that measurement of TJP-2 expression might have utility in the staging of liver cancer. <h3>Disclosure of Interest</h3> None Declared
A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL)
Authors: Raya Mawad, Ajay K. Gopal, Oliver W. Press, David G. Maloney, Stephen H. Petersdorf, Troy Wadsworth, Trevor W. Dennie, Yoshio Inoue, Karl J. Schultheiss, Kiarash Kojouri, Kelly M. Smith, Britt Kammerer, John M. Pagel
Journal: Blood (2013)
Prognostic factors in glioblastoma patients treated with the nitrosourea fotemustine at first relapse after the Stupp regimen: results from the GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology)
Authors: M. Santoni, G. Lombardi, S. Scoccianti, M.G. Fabrini, A. Silvani, V. Villani, A. Marinelli, I. Lolli, M. Balducci, M. Arcicasa, M. Salvati, A.P. Sponghini, S. Vallarelli, M. Caroli, F. Imbesi, D. Bilancia, M. Faedi, S. Cascinu, R. Soffietti, R. Rudà
Journal: Annals of Oncology (2015)
Presence of an Immune System Increases Anti‐Tumor Effect of Ag Nanoparticle Treated Mice
Authors: Bella B. Manshian, Julio Jimenez, Uwe Himmelreich, Stefaan J. Soenen
Journal: Advanced Healthcare Materials (2016)

To date, most nanomedical studies rely on the use of immune-deficient mice in which the contribution of the immune system on the applied therapy is ignored. Here, the degradation of silver nanoparticles (Ag NPs) is exploited as a means to treat subcutaneous tumor models in mice. To investigate the impact of the immune system, the same tumor cell type (KLN 205 murine squamous cell carcinoma) is used in a xenograft model in NOD SCIDγ immune-deficient mice and as a syngeneic model in immune-competent DBA/2 mice. The Ag NPs are screened for their cytotoxicity on various cancer cell lines, indicating a concentration-dependent induction of oxidative stress, mitochondrial damage, and autophagy on all cell types tested. At subcytotoxic concentrations, prolonged cellular exposure to the Ag NPs results in toxicity due to NP degradation and the generation of toxic Ag+ ions. At subcytotoxic conditions, the NPs are found to cause inflammation in vitro. Similar results are obtained in the immune-competent mouse model, where clear inflammation is observed after treatment of the implanted tumors with Ag NPs. This inflammation leads to an ongoing antitumoral effect, which results in a significantly reduced tumor growth compared to Ag NP-treated tumors in an immune-deficient model.
The Importance of Be(ginn)Ing Naïve: Implications for Cancer Immune-Gene Therapy
Authors: Nicoletta Cieri, Barbara Camisa, Fabienne Cocchiarella, Elena Provasi, Zulma Magnani, Attilio Bondanza, Anna Mondino, Fulvio Mavilio, Silvio Bicciato, Alessandra Recchia, Chiara Bonini
Journal: Blood (2011)
SGN-35, an Anti-CD30 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity for the Treatment of CD30+ Malignancies.
Authors: Kevin J. Hamblett, Jeremy Barton, Charles G. Cerveny, Jamie B. Andreyka, Kim M. Kissler, Nicole M. Okeley, Ivan Stone, May K. Sutherland, Michael M. Sun, Peter D. Senter, Alan F. Wahl, Nathan C. Ihle
Journal: Blood (2005)
Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B.
Authors: Howard S. Hochster, Edie Weller, Randy D. Gascoyne, Teresa S. Ryan, Thomas M. Habermann, Leo I. Gordon, Stanley R. Frankel, Sandra J. Horning
Journal: Blood (2005)
SP0158 Technological Challenges in Implementing e-Health
Authors: T. Dawson
Journal: Annals of the Rheumatic Diseases (2016)

This presentation will focus on the story of a UK SME, Rescon Technologies, that started with an idea to harness history at source in 2011. This involved developing a tool to allow patients to capture their own medical history in real-time, in an accessible easy to use format. It will cover the journey from idea generation to co-development pilots through to going to market in the UK. This will include examples of how opportunities need to be embraced to allow obstacles to be overcome in getting a product to market in a fragmented health and social care ecosystem. Specific topics that will be addressed are: 1. The issues around contemporary history taking; 2. The rise of patient reported outcome measures; 3. History as a diagnostic and prognostic tool; 4. How history relates to new outcome commissioning models; 5. Accessibility; 6. User interfaces and user experience; 7. Segmentation, quantification and digitisation; 8. Co-production; 9. System and workflow integration; 10. Competition, interoperability, and collaboration; 11. Health economics; 12. Advantages of an integrated information technology approach. The presentation will conclude with recommended considerations before embarking on the journey of turning an idea or aspiration into a sustainable product that will improve health or social care. <h3>Disclosure of Interest</h3> T. Dawson Shareholder of: Rescon Technologies
Prediction of Relapse Risk by Day 100 BCR-ABL Quantification after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia.
Authors: Marie T. Rubio, Vahid Asnafi, Eric Delabesse, Gandhi Damaj, Nathalie Dhedin, Bruno R. Varet, Agnes Buzyn, Elizabeth A. Macintyre
Journal: Blood (2005)
Managing recovery from concussion
Authors: John Brooks, Simon Kemp, Aisha Newth, Richard Sylvester
Journal: BMJ (2016)

#### What you need to know



A graduated return to sport is recommended after injury (see infographic), such as low risk training drills



A 16 year old hit his head on the knee of another player during a sports match two days ago. He was taken to the emergency department, diagnosed with concussion, and discharged with head injury advice. His mother is concerned that he still has a headache and difficulty concentrating. He wants to return to playing sport as soon as possible.

Concussion is a clinical diagnosis made after a head injury with consequent associated signs, symptoms, and neurological or cognitive impairment1 (infographic). These usually have a rapid onset and typically recover spontaneously within 7-10 days. Loss of consciousness occurs in <10% of incidents.2 Collision and high impact sports,3 such as rugby, hockey, soccer, motor sports, boxing, and horse riding, carry a higher risk. Most recommendations on the management and recovery from concussion are based on international expert consensus; in the absence of strong evidence.1 Routine brain imaging is not advised.

Ask how the injury was sustained. Was there significant head trauma or other clinical features suggestive of concussion? The most …
Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma.
Authors: Sergio Siragusa, William Morice, Morie A Gertz, Robert Kyle, Philip R. Greipp, John A. Lust, Thomas E Witzig, Martha Q. Lacy, Steven R. Zeldenrust, S. Vincent Rajkumar, Suzanne R. Hayman, Francis Buadi, Stephen J. Russell, Shaji Kumar, David Dingli, Angela Dispenzieri
Journal: Blood (2009)
Inhibition of T Cell Proliferation By Granulocyte Membrane-Associated Proteinase 3 Is Reversed By Blocking the Interaction of Calreticulin with LRP on T Cells
Authors: Tian-Hui Yang, Lisa S. St. John, Karen Clise-Dwyer, Kathryn Ruisaard, Gheath Alatrash, Jeffrey J. Molldrem
Journal: Blood (2014)
High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL)
Authors: Jae-Ho Yoon, Hee-Je Kim, Byung Sik Cho, Seung-Ah Yahng, Seung-Hwan Shin, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min
Journal: Blood (2015)
Abstract 19720: Jay D. Coffman Early Career Investigator Award: Comparative Efficacy of Initial Endovascular Revascularization vs. Supervised Exercise Training in Patients With Intermittent Claudication: A Meta-analysis of Randomized Controlled Trials
Authors: Ambarish Pandey, Subhash Banerjee, Christian Ngo, Purav Mody, Steven Marso, Emmanouil S Brilakis, Ehrin J Armstrong, Jay Giri, Marc P Bonaca, Aruna Pradhan, Dharam Kumbhani
Journal: Circulation (2015)

Introduction: Current guidelines recommend supervised exercise training (SET) as the initial treatment modality for patients with intermittent claudication (IC), in addition to optimal medical therapy. The role of endovascular revascularization (ER) as a primary treatment option has been controversial. We performed a meta-analysis to compare the efficacy of initial ER vs. initial SET in patients with IC using data from randomized controlled trials. Methods: The primary outcome was treadmill-measured maximum walking distance (MWD) at the end of follow-up. Secondary outcomes included resting ankle brachial index (ABI) and treadmill-measured ischemic claudication distance (ICD) on follow-up. Risk of adverse limb events (revascularization, amputations) was also compared between the two groups. Random effects models were used for all analyses. Results: We included 1,145 patients from nine trials with a mean follow up duration of 13.7 months (42% aortoiliac lesions; 35% stent use; mean baseline ABI 0.64 vs. 0.67 for ER vs. SET). Follow-up MWD was not significantly different between patients undergoing ER vs. SET [Weighted mean difference (WMD) (95% CI): 19.1 m (-79.6 to 117.8 m); publication bias p=0.86]. Metaregression did not identify significant differences based on stent use or presence of aortoiliac disease. ICD was also similar between the two groups [WMD (95% CI): 36.1 m (-99.4 to 171.5 m)]. In contrast, patients undergoing ER had higher resting ABI on follow-up [WMD (95% CI): 0.14 (0.11 to 0.17), p&lt;0.0001]. Adverse limb event rates were similar [5.4% vs. 8.2%, p=0.21]. Conclusion: Compared with initial SET, initial ER significantly improves resting ABI values. Although longer walking distance and lower rates of adverse limb events also appeared favorable for ER, these differences were not statistically significant in these intermediate term studies. Longer-term studies and those incorporating contemporary revascularization techniques are necessary.
OP0087 The Association of Extra-Articular Manifestations with Disease Duration in Axial Spa: Results from The (Be-) Giant Cohort and The Aspect Study
Authors: G. Varkas, H. Cypers, N. Vastesaeger, L. Van Praet, P. Carron, F. Van den Bosch, D. Elewaut
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The prevalence of extra-articular manifestations (EAMs) in ankylosing spondylitis (AS) is well-known. However, as the diagnosis of axial spondyloarthritis (AxSpA) is now made much earlier in the disease the prevalence of the EAMs may be different. Moreover, the introduction of anti-TNF therapy may have altered the incidence of EAMs. <h3>Objectives</h3> to assess the association of EAMs with disease duration in AxSpA patients (n=215) in the post-anti-TNF era compared to a historic cohort of Belgian AS patients (n=847) from the pre-anti-TNF era. <h3>Methods</h3> The BelGian Inflammatory Arthritis and spoNdylitis cohorT (Be-Giant) and The Ghent Inflammatory Arthritis and spoNdylitis cohorT (GIANT) are post-anti-TNF observational cohorts that include consecutive patients since 2010, diagnosed with AxSpA by their treating rheumatologist. Patients who fulfill the ASAS classification criteria, are prospectively followed every 6 months. Follow-up consisted of patient-reported outcomes, a standardized clinical examination (peripheral joints, entheses, axial metrology), standard laboratory analysis and imaging. The ASPECT cohort is a Belgian pre-anti-TNF cross-sectional AS database containing information on 847 patients who fulfilled the New York modified criteria for AS between February 2004 and February 2005. <h3>Results</h3> In the (Be-)Giant cohort and ASPECT cohort respectively 47% and 67.9% of patients were male. Mean age was 34.5 (SD 9.6) in the (Be-)Giant cohort and 44.6 (SD 12.1) in the ASPECT cohort. Mean symptom duration was respectively 7.9 and 18.5 years. HLA-B27 was positive in respectively 76.5% and 83% of patients with HLAB27 determination. In a cross-sectional analysis of the baseline data of 215 AxSpA patients from the (Be-) GIANT cohorts, about 66.5% (143/215) of patients had not experienced any EAMs compared to only 58% (491/847) of AS patients in the ASPECT cohort. Additionally, 71.5% (112/144) of patients with a symptom duration of less than 10 years had not experienced any EAMs at baseline in the (Be-)GIANT cohort. However, in patients with more than 10 years of symptom duration, only about half of patients remained EAM- free (P=0.021). Similarly, in patients from the ASPECT cohort with a disease duration of less than 10 years, 70% of patients (304/434) had not experienced any EAM at baseline, whereas only 39% (79/203) of patients remained EAM- free after 20 years of disease. A subanalysis of 118 newly diagnosed non-radiographic AxSpA (nr -AxSpA) patients demonstrated a prevalence of 70.3% (83/118) of EAM-free patients at diagnosis. <h3>Conclusions</h3> The prevalence of extra-articular manifestations seems to increase with disease duration both in the pre-anti-TNF and the post-anti-TNF era, and may be linked to longer cumulative exposure to inflammation. <h3>Disclosure of Interest</h3> None declared
Efficacy and Safety of Colistin for the Treatment of Infections Caused by Multidrug-Resistant Isolates of Pseudomonas Aeruginosa Sensitive to Colistin in Patients with Haematological Malignancy; a Matched-Pair Analysis.
Authors: Nadira Durakovic, Ana Boban, Mirando Mrsic, Dubravka Sertic, Ranka Serventi Seiwerth, Damir Nemet, Boris Labar
Journal: Blood (2007)
Keratinocyte Growth Factor Increases Thymic Output of Naïve T-Cells after Total Body Irradiation and Autologous Peripheral Blood Progenitor Cell Transplantation in Rhesus Macaques.
Authors: Ruth Seggewiss, Karin Lore, F. Javier Guenaga, Stefania Pittaluga, Joseph J. Matappallil, David Ambrozak, Robert T. Bailer, Richard A. Koup, Robert E. Donahue, Bruce R. Blazar, Georg A. Hollander, Daniel C. Douek, Cynthia E. Dunbar
Journal: Blood (2005)
Computerized Cognitive Training in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review and Meta-Analysis
Authors: Nicole T.M. Hill, Loren Mowszowski, Sharon L. Naismith, Verity L. Chadwick, Michael Valenzuela, Amit Lampit
Journal: American Journal of Psychiatry (2016)

Objective: Previous meta-analyses indicate that computerized cognitive training (CCT) is a safe and efficacious intervention for cognition in older adults. However, efficacy varies across populations and cognitive domains, and little is known about the efficacy of CCT in people with mild cognitive impairment or dementia. Method: The authors searched Medline, Embase, PsychINFO, CINAHL, and CENTRAL through July 1, 2016, for randomized controlled trials of CCT in older adults with mild cognitive impairment or dementia. Overall cognition, individual cognitive domains, psychosocial function, and activities of daily living were pooled separately for mild cognitive impairment and dementia trials. Results: The overall effect on cognition in mild cognitive impairment across 17 trials was moderate (Hedges’ g=0.35, 95% CI=0.20–0.51). There was no evidence of publication bias or difference between active- and passive-controlled trials. Small to moderate effects were found for global cognition, attention, working memory, learning, and memory, with the exception of nonverbal memory, and for psychosocial functioning, including depressive symptoms. In dementia, statistically significant effects were found on overall cognition (k=11, g=0.26, 95% CI=0.01–0.52) and visuospatial skills, but these were driven by three trials of virtual reality or Nintendo Wii. Conclusions: CCT is efficacious on global cognition, select cognitive domains, and psychosocial functioning in people with mild cognitive impairment. This intervention therefore warrants longer-term and larger-scale trials to examine effects on conversion to dementia. Conversely, evidence for efficacy in people with dementia is weak and limited to trials of immersive technologies.
Developing an Algorithm for Monitoring Chimerism after Allogeneic Bone Marrow Transplantation - A Single Centre Experience.
Authors: Mammen Chandy, S. Shanmugapriya, Poonkuzhali Balasubramaniam, S. SatheeshKumar, R.V. Shaji, Vikram Mathews, Biju George, Auro Vishwabandya, Alok Srivastava
Journal: Blood (2005)
Effects of aerobic exercise and diet intervention on glycaemic control and liver fat content in men and women aged 50–65 years with prediabetes and non-alcoholic fatty liver disease: a multicentre, randomised controlled trial
Authors: Sulin Cheng, Jun Ge, Can Zhao, Petri Wiklund, Shenglong Le, Yifan Yang, Dandan Ke, Na Wu, Xiao Tan, Jianqin Sun, Renwei Wang, Yongyong Shi, Ronald Borra, Riitta Parkkola, Dajiang Lu
Journal: The Lancet Diabetes & Endocrinology (2016)
Profiles of Th1, Th2, Th17 and Treg Cells in Patients with Chronic Idiopathic Thrombocytopenic Purpura.
Authors: Rong-Fu Zhou, Jian Ou-yang, Da-Yu Chang, Jing-Yan Xu, Bing Chen, Yong-Gong Yang, Qi-Guo Zhang, Xiao-Yan Shao
Journal: Blood (2008)
FRI0191 Biosimilar Candidate ABP 501: Additional Efficacy Analyses from The Phase 3 Study: Table 1.
Authors: S. Cohen, N. Zhang, P. Kaur
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> ABP 501 is being developed as a biosimilar candidate to adalimumab, a fully human recombinant monoclonal antibody. Evidence from analytical and pharmacokinetic comparisons indicates that ABP 501 is highly similar to adalimumab. Results of efficacy and safety from a phase 3 study comparing ABP 501 with adalimumab in subjects with rheumatoid arthritis (RA) have been previously presented.<sup>1,2</sup> <h3>Objectives</h3> To report descriptive results from additional efficacy analysis based on clinical disease activity index (CDAI) and simplified disease activity index (SDAI) composite indices as well as results for the ACR individual components. These analyses provide information on alternate methods for disease management. <h3>Methods</h3> This was a randomized, double-blind, active-controlled study in adult subjects with moderate to severe RA who had an inadequate response to methotrexate. Subjects were randomized in a 1:1 ratio (ABP 501: n=264; adalimumab: n=262) to receive either ABP 501 or adalimumab 40 mg subcutaneously every 2 weeks. Details of the study design have been previously reported.<sup>1</sup> For these analyses descriptive summaries of CDAI, SDAI and individual American College of Rheumatology response criteria (ACR) components were generated. <h3>Results</h3> Baseline characteristics were well balanced between groups. At week 24, the mean (SD) CDAI improvement from baseline was 25.94 (12.62) for ABP 501 and 25.06 (12.02) for adalimumab. At week 24, the mean (SD) SDAI improvement from baseline was 26.57 (12.97) for ABP 501 and 25.64 (12.31) for adalimumab. Results for CDAI, SDAI and individual ACR components at baseline and week 24 are shown in the Table. The overall safety and immunogenicity profile of ABP 501 was comparable to that of adalimumab and has been previously reported.<sup>1,2</sup> <h3>Conclusions</h3> These additional analyses confirm that the of efficacy ABP 501 is comparable to adalimumab in multiple clinical characterisitics providing further evidence that ABP 501 is similar to adalimumab. <h3>References</h3> Cohen et al. Presented at: American College of Rheumatology Annual Meeting; November 2015; San Francisco, CA. Abstract 2054. Matsumoto et al. Presented at: American College of Rheumatology Annual Meeting; November 2015; San Francisco, CA. Abstract 2757. <h3>Acknowledgement</h3> Monica Ramchandani, PhD for medical writing. <h3>Disclosure of Interest</h3> S. Cohen Consultant for: Amgen, N. Zhang Shareholder of: Amgen, Employee of: Amgen, P. Kaur Shareholder of: Amgen, Employee of: Amgen
X-perience – A radiographic viewing platform displaying profiles of cadavers for educational purposes
Authors: E.N. an Riogh, G. Perry, J.F.X. Jones, R.H. Stern, A.N. an Riogh, P.Mc Mahon, None A.Tattersall, M. Heduan, N. Giannotti, M. Davis
Journal: International Journal of Surgery (2016)
A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes
Authors: Jing Fang, Xiaona Liu, Lyndsey Bolanos, Brenden Barker, Carmela Rigolino, Agostino Cortelezzi, Esther Natalie Oliva, Kyle J MacBeth, Kakajan Komurov, Daniel T Starczynowski
Journal: Blood (2014)
P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis
Authors: Hossein Borghaei, Julie Brahmer, Leora Horn, Neal Ready, Martin Steins, Enriqueta Felip, Luis Paz-Ares, Xx Xx, Fabrice Barlesi, Scott Antonia, Jérome Fayette, Naiyer Rizvi, Lucio Crino, Martin Reck, Wilfried Ernst Erich Eberhardt, Matthew Hellmann, Kaushal Desai, Ang Li, Diane Healey, David Spigel, Clarissa Mathias
Journal: Journal of Thoracic Oncology (2016)